Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Inhaled Nitric Oxide 75 mcg/kg IBW/hr Clear all
Withdrawn Phase 3 Interventional

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

NCT03602781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, iNO
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 5, 2026, 7:19 PM EDT
Not listed Phase 2 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Long Term Follow Up
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 5, 2026, 7:19 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 5, 2026, 7:19 PM EDT
Completed Phase 2 Interventional

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 5, 2026, 7:19 PM EDT